Q32 Bio (Phase 2 Complement Inhibitor Adx-097) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Q32 Bio (Phase 2 Complement Inhibitor Adx-097) General Information

Description

A phase 2 drug intended to cure rare kidney disease

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Waltham, MA
  • United States
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Corporate Office
  • Waltham, MA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Q32 Bio (Phase 2 Complement Inhibitor Adx-097) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Q32 Bio (Phase 2 Complement Inhibitor Adx-097)‘s full profile, request access.

Request a free trial

Q32 Bio (Phase 2 Complement Inhibitor Adx-097) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Q32 Bio (Phase 2 Complement Inhibitor Adx-097)‘s full profile, request access.

Request a free trial

Q32 Bio (Phase 2 Complement Inhibitor Adx-097) FAQs

  • Where is Q32 Bio (Phase 2 Complement Inhibitor Adx-097) headquartered?

    Q32 Bio (Phase 2 Complement Inhibitor Adx-097) is headquartered in Waltham, MA.

  • What industry is Q32 Bio (Phase 2 Complement Inhibitor Adx-097) in?

    Q32 Bio (Phase 2 Complement Inhibitor Adx-097)’s primary industry is Buildings and Property.

  • Is Q32 Bio (Phase 2 Complement Inhibitor Adx-097) a private or public company?

    Q32 Bio (Phase 2 Complement Inhibitor Adx-097) is a Private company.

  • What is the current valuation of Q32 Bio (Phase 2 Complement Inhibitor Adx-097)?

    The current valuation of Q32 Bio (Phase 2 Complement Inhibitor Adx-097) is .

  • What is Q32 Bio (Phase 2 Complement Inhibitor Adx-097)’s current revenue?

    The current revenue for Q32 Bio (Phase 2 Complement Inhibitor Adx-097) is .

  • Who are Q32 Bio (Phase 2 Complement Inhibitor Adx-097)’s investors?

    Q32 Bio has invested in Q32 Bio (Phase 2 Complement Inhibitor Adx-097).

  • When was Q32 Bio (Phase 2 Complement Inhibitor Adx-097) acquired?

    Q32 Bio (Phase 2 Complement Inhibitor Adx-097) was acquired on 01-Dec-2024.

  • Who acquired Q32 Bio (Phase 2 Complement Inhibitor Adx-097)?

    Q32 Bio (Phase 2 Complement Inhibitor Adx-097) was acquired by Akebia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process